Today the pipelines of many pharmaceutical companies contain a wide range of both small molecule and antibody-based drugs that bind to and/or inhibit many cell surface receptors, proteins and enzymes required for tumor growth and proliferation. The gene discussed is CD177; the disease is neoplasm.